CLINUVEL Strategic Update II
Melbourne, Australia, 12 April 2021 CLINUVEL today announced its second Strategic Update,...
Read MoreCLINUVEL Kommuniqué II
Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...
Read MoreCLINUVEL Communiqué II
Dear shareholders, friends We welcome many new shareholders, especially the large number...
Read MoreChair's Letter I
Direction and horizon In the last weeks, I have had investor questions...
Read MoreMedia Release - CLINUVEL Expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...
Read MoreSCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
CLINUVEL today announced that it has reached agreement with clinical and academic...
Read MoreInvestor Presentation - Daiwa Investment Conference Tokyo 2021
10 March 2021 – Melbourne, Australia On 10 March 2021 CLINUVEL presented...
Read MoreAppendix 3Y Change of Director's Interest Notice
CLINUVEL PHARMACEUTICALS LTD today released the attached Appendix 3Y which relates to...
Read MoreAppendix 3Y Change of Director's Interest Notice
Information or documents not available now must be given to ASX as...
Read MoreSCIENTIFIC COMMUNIQUÉ IX
Beyond Pigment, the Melanocortin 1 Receptor (MC1R) in DNA Repair March 2021...
Read MoreCLINUVEL Reports Tenth Consecutive Half Year Net Profit
KEY HIGHLIGHTS, HALF YEAR ENDED 31 DECEMBER 2020 Consolidated Entity Result Change...
Read MoreAppendix 4D Half Year Report
Results For Announcement To The Market ($A’000) Revenues from continuing activities Increased...
Read MoreFinancial Results Half Year Ended 31 December 2020
Operations Update I Webinar CLINUVEL PHARMACEUTICALS LTD CLINUVEL PHARMACEUTICALS LTD will host...
Read MoreSCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read MoreKommuniqué I
Liebe Freunde, Aktionäre, Wir sind in ein neues Jahr eingetreten, eines voller...
Read More